SeroTag platform and NavigAID pipeline
Using its proprietary SeroTag® biomarker discovery platform and range of NavigAID patient stratification products, Protagen can identify novel, valuable biomarkers to support pharmaceutical development.
Protagen collaborates with organizations to co-develop valuable commercialized products and companion diagnostic tools, designed to enable better personalized treatment strategies based on more targeted therapies.
Thanks to its experience, pioneering bioscience techniques, extensive scientific expertise and broad patent portfolio, Protagen is also actively expanding its own pipeline of critically informative biomarkers via its SeroTag® platform. Its expanding portfolio of NavigAID disease-specific stratification arrays also allow for enhanced therapeutic development strategies based on targeted patient sub-groups.
With an increase in the development and use of immunotherapies, as well as the concurrent need to improve therapeutic outcomes and reduce the impact of side-effects, Protagen is well positioned to support partners working in the areas of immuno-oncology and autoimmune disease. With a strong understanding of the interdependence of immuno-oncology and autoimmune disease, and a comprehensive portfolio of unique technologies and expertise, companies can gain answers to some of the most pressing questions underpinning their drug development challenges:
- Why do some people respond favorably to immunotherapies while others fail to respond?
- Why do some patients receiving immunotherapy develop debilitating autoimmune diseases?
- Why is it so challenging to develop effective therapeutics for the most severe autoimmune diseases?
To find out how Protagen can support your therapeutic development project to enable better response prediction, disease stratification, patient monitoring and early detection of adverse events, contact us now.